Key result
Radiation therapy for retroperitoneal sarcoma lacks optimal data to guide management, but when used in selected patients, it should be delivered preoperatively rather than postoperatively.
Why the study?
Recurrence remains common after surgery for retroperitoneal sarcoma, and the role of radiation therapy to improve local control is controversial with suboptimal existing data.
Does radiation therapy improve local control in patients with retroperitoneal sarcoma?
Does radiation therapy improve local control in patients with retroperitoneal sarcoma?
Radiation therapy for retroperitoneal sarcoma remains controversial and should be delivered preoperatively if used in selected patients based on multidisciplinary input.
Retroperitoneal sarcoma comprises a small subset of all soft tissue sarcoma and includes various histopathologic subtypes, each with unique patterns of behavior and differential risks for local recurrence and hematogenous metastatic spread. The primary treatment modality is surgery, although even with complete macroscopic resection, recurrence is common. The rationale for the addition of radiotherapy to resection is to improve local control; however, the use of radiation therapy for retroperitoneal sarcoma is controversial, and existing data are suboptimal to guide management. Treatment decisions should be determined with multidisciplinary input and shared decision-making. When used in selected patients, radiation therapy should be delivered preoperatively; postoperative treatment is not recommended.
No takes yet. Share an insight, caveat, or question.
Salerno et al. (2022) conducted a review in Retroperitoneal sarcoma. Radiation therapy was evaluated. Radiation therapy for retroperitoneal sarcoma lacks optimal data to guide management, but when used in selected patients, it should be delivered preoperatively rather than postoperatively.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: